💥Descubre en 30 segundos quiénes somos y qué es lo que hacemos. Y recuerda si eres médico o especialista en #Feo #Para o #CarcinomaSuprarrenal recomiéndanos a tus pacientes para que sepan que no están solos 🙏 #Net #enfermedadesraras youtu.be/TNUJsieMHaY?si…

Ready for Grupo GETNE stars at #ASCO24 ⁉️ Alejandro Garcia presents the LEVEL study design and accrual. First trial evaluating the role of 177Lu-edotreotide vs Everolimus in lung & thymic WD-NET. NET- ESPAÑA ITM Isotope Technologies Munich SE

Starting the morning with the NETs session! Always a luxury to learn from the best! Jaume Capdevila Prof Chrissie Thirlwell #ESMO2024 #NETs

Another challenging day ahead in #ESMO24! Today we start today with thyroid cancer with the best hosts Laura Locati and Marcia Brose! Grupo GETNE AECAT

See you all at the poster area this Monday! #ESMO24 👇👇👇👇

El grupo NET-VHIO se estrena en la cita nacional más importante en TNE, el Simposio #GETNE24 en Santiago de Compostela.

📢 Just out: MGMT-NET study! ALKY agents show better outcomes in dMGMT NETs, while MGMT has no impact on Ox regimens. Should MGMT testing become standard? More evidence needed. What about DAXX/ATRX or other biomarkers? A fascinating study raising new questions! 🧬✨ Grupo GETNE

Thanks Udhayvir Grewal for sharing our review! However, best first line treatment combination remains unclear for epNECs. Will results from ongoing trials with ICI and DLL3 BiTEs change the 1L "boring" Platinum + Etoposide? I hope so!

⏱️⌛️ TIC, TAC!!!! Queda justo un mes para el XI Simposio Nacional de Genómica 🧬💉🩸🩺 Aplicada en Oncología 💊🔬🧪(medicinadeprecisionenoncologia.es). Nos lo pasaremos bien aprendiendo con los mejores ponentes y en el auditorio del CNIO Stop Cancer Para inscripciones pulsa aquí: 👉

Excellent ENETS-NANETS morning session with two superstars Thor Halfdanarson and Jaume Capdevila at #enets25 🚨Last trials update in NENs (COMPETE, STARTER-NET, 212Pb-DOTA...) 🆕 Upcomming trials (ADC in NECs, DLL3-BiTEs Grupo GETNE) 🔮Future possible players (non-peptide drug conjugate)

We’re hiring! Join our lab to work on cutting-edge TCR-based therapies in neuroendocrine tumors (NETs). Passionate about immunotherapy and translational cancer research? Apply by April 17, 2025! #Postdoc #Immunotherapy #CancerResearch #TCR #NETs #Hiring reclutamento.ict.uniba.it/contratti-di-r…

Nuevos tratamientos en desarrollo en neoplasias neuroendocrinas #ASCO25 👩🏼‍🔬ABBV-706 (SEZ6 ADC) ✅️Expresión de SEZ6 en NET y NEC ✅️ORR 36%, PFS 7m ✅️Actividad en carcinoma medular de tiroides. ✅️Continua desarrollo en monoterapia +/- budigalimab +/- quimio.